US Pharma MarketingCellares and Papillon partner for PPL-001 manufacturing automation
Cellares and Papillon Therapeutics have entered into a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for FA, a rare inherited neurodegenerative disorder.
Cellares and Papillon Therapeutics have entered into a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for FA, a rare inherited neurodegenerative disorder.
Source: Pharmaceutical Technology